Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $5.2850 (-1.8%) ($5.0505 - $5.4635) on Tue. Jun. 23, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.49% (three month average) | RSI | 42 | Latest Price | $5.2850(-1.8%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.2% a day on average for past five trading days. | Weekly Trend | HTBX declines -6% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) ARKG(29%) XBI(29%) ARKK(28%) ACES(25%) IBB(25%) | Factors Impacting HTBX price | HTBX will decline at least -3.245% in a week (0% probabilities). VXX(-16%) VIXM(-12%) UUP(-11%) UNG(-8%) XLP(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.245% (StdDev 6.49%) | Hourly BBV | 0 () | Intraday Trend | -3.3% | | | |
|
1 - 5 Day Possible Target | $-16.82(-418.26%) | Resistance Level | $5.84 | 5 Day Moving Average | $5.32(-0.66%) | 10 Day Moving Average | $5.36(-1.4%) | 20 Day Moving Average | $5.84(-9.5%) | To recent high | -32% | To recent low | 2% | Market Cap | $581m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |